Trials / Completed
CompletedNCT01455896
A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650
A Randomized, Multi-Center Study to Evaluate Cardiovascular Outcomes With ITCA 650 in Patients Treated With Standard of Care for Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 4,156 (actual)
- Sponsor
- Intarcia Therapeutics · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
Phase 3 study to Evaluate cardiovascular outcomes in patients with type 2 diabetes treated with ITCA 650.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ITCA 650 | ITCA 650 |
| OTHER | ITCA placebo | ITCA placebo |
Timeline
- Start date
- 2013-03-01
- Primary completion
- 2016-03-01
- Completion
- 2016-03-01
- First posted
- 2011-10-20
- Last updated
- 2017-01-27
Locations
42 sites across 9 countries: United States, Bulgaria, Denmark, Finland, Germany, Poland, Slovakia, South Africa, Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT01455896. Inclusion in this directory is not an endorsement.